Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix

Launched by M.D. ANDERSON CANCER CENTER · Jan 21, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on collecting important information about patients with a type of cervical cancer known as neuroendocrine carcinoma. By gathering data on different patient experiences, treatments, and outcomes, the study aims to improve our understanding of this rare cancer and how it affects individuals at various stages of their journey.

To participate, individuals must have a history of cervical cancer that includes a neuroendocrine component, such as small cell or large cell neuroendocrine carcinoma. Patients can be at any stage of their treatment, whether they are just starting, currently receiving treatment, or in follow-up care. The study is open to patients from anywhere in the world, regardless of language or background, and even family members of those who have passed away from this cancer can take part. Participants can expect to share their medical history and experiences, which will contribute to a larger understanding of neuroendocrine cervical cancer and potentially help improve future care for others.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Patients with a personal history of cervical cancer with any portion of neuroendocrine component (including mixed tumors) of the following histologic subtypes:
• • Small cell neuroendocrine carcinoma
• • Large cell neuroendocrine carcinoma
• • Undifferentiated high-grade neuroendocrine carcinoma
• • Patients may be in any stage of treatment, surveillance or recurrence at the time of initial participation in the study
• • Patients with all stages of disease are considered eligible
• • Patients who do not speak English can be eligible if accompanied by an institutional interpreter
• • Patients who are receiving or have received treatment at any facility, including but not limited to M. D. Anderson Cancer Center are eligible
• • Patient may be residents of any country and be of any ethnic background
• • Patients who request to participate in the study, regardless of the method by which they learned of it, are eligible to participate, including, but not limited to patients who seek participation via the website
• • Next of kin or legal authorized representatives of patients who are deceased but had a history of neuroendocrine carcinoma (NEC) of the cervix are eligible to participate
• • Next of kin or legal authorized representatives of patients must read and speak English
• Exclusion Criteria:
• • Patients with other histologic subtypes of NEC of the cervix including typical and atypical carcinoid tumors